---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004193"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:37:36.248212+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiMedx reaffirms Q4/FY2022 sales; warns of Medicare reimbursement risk for skin substitutes

## Summary
- Q4 2022 net sales expected $73M-$76M; FY2022 $266M-$269M, unchanged from Nov 2022 guidance.
- About 28% of 2022 sales from private physician office; ~75% of that reimbursed by CMS, over 90% is EPIFIX.
- Received FDA TRG letter confirming EPIFIX as Section 361 product in Dec 2022; seeking confirmation for EPICORD.
- Restructuring headcount reductions expected to cut annualized costs by ~$5M; sales force realigned for productivity.
- Entered distribution partnership with Gunze Medical for EPIFIX in Japan; appointed Ricci Whitlow as COO.

## SEC filing metadata
- accession: 0001193125-23-004193
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/0001193125-23-004193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/d442188d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004193
- JSON: https://secwatch.observer/filing/0001193125-23-004193.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004193.txt

## Key facts
- Earnings Releases
  MIMEDX GROUP, INC. updated its fourth quarter of 2022 and full year 2022 guidance (reaffirmed).
  - Period: fourth quarter of 2022 and full year 2022
  - Guidance: reaffirmed
  - Result: guidance update
  source text: reaffirming its fourth quarter of 2022 and full year 2022 net sales expectations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312523004193/0001193125-23-004193-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.